Drug: Lipitor
Company: Pfizer
Total spend Q1, 2012: $44.5 million
Total spend Q1, 2011: $71.9 million
Watch the TV commercial here >>

Lipitor lost patent protection in November, and while the company made some efforts to hold onto market share, it is clear from the reduced ad spend numbers that Lipitor has also lost its luster for Pfizer ($PFE). The company has been quietly winding down its marketing of the cholesterol fighter as generics makers have stripped it of sales. In the first quarter, Lipitor not only lost its hold on first place as the top selling drug--that honor went to Bristol-Myers Squibb's ($BMY) Plavix--it fell all the way to 14th place with $841 million in sales, surpassed even by its own generic copycats, which brought in $950 million.


Suggested Articles

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.